Abelacimab 150 mg, a unique Factor XI/XIa inhibitor from Anthos Therapeutics, showcased a 67% decline in significant or notably relevant non-major bleeding versus Rivaroxaban in atrial fibrillation patients.

Novartis research suggests that remibrutinib, an oral medication, can effectively ease symptoms of chronic spontaneous urticaria as early as the second week of treatment.

Ocugen, Inc. declares commencement of Phase 1/2 trial after first administration on patient for OCU410ST - a modifier gene therapy for Stargardt Disease, assessing its safety and effectiveness.

Sana Biotech Reveals FDA Approval of New Drug Application for SC291, a Hypoimmune-modified, Targeting CD19, Allogeneic CAR T Treatment, Targeted for Lupus Nephritis, Extrarenal Lupus, and ANCA-linked Vasculitis Patients.

US FDA has given the green light to Takeda's ADZYNMA (recombinant-krhn, ADAMTS13) for the management of Congenital Thrombotic Thrombocytopenic Purpura (cTTP).

Boston Pharma shares promising Phase 2a results for potential once-a-month BOS-580 treatment in NASH and its impact on diabetic groups, showcased at the 2023 AASLD Liver Meeting.

Sirius Therapeutics reports its application to initiate the primary clinical testing of Factor XI siRNA, an advanced, long-lasting anticoagulant for blood clot issues.

Trishula Therapeutics kickstarts Phase 2 study of TTX-030, a compound directed against CD39, in initial treatment of patients with advanced pancreatic cancer.

Phase III EMERALD-1 trial reveals Imfinzi combined with bevacizumab achieved primary objective by improving progression-free survival in advanced liver cancer patients who qualify for embolisation.

Eccogene acquires unique licensing rights from AstraZeneca to advance and market ECC5004, a small molecule GLP-1 receptor agonist, for cardiovascular metabolic conditions.

Allgenesis reports promising initial safety and effectiveness results for AG-73305 phase 2a trial tackling Diabetic Macular Edema, presented at the American Academy of Ophthalmology.

Takeda has announced FDA approval for its oral drug, FRUZAQLA™ (fruquintinib), designed to treat adults with metastatic colorectal cancer who have previously received chemotherapy, anti-VEGF, and applicable anti-EGFR therapies.